These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 34928709)

  • 21. Neoadjuvant Dual Checkpoint Inhibitors vs Anti-PD1 Therapy in High-Risk Resectable Melanoma: A Pooled Analysis.
    Mangla A; Lee C; Mirsky MM; Wang M; Rothermel LD; Hoehn R; Bordeaux JS; Carroll BT; Theuner J; Li S; Fu P; Kirkwood JM
    JAMA Oncol; 2024 May; 10(5):612-620. PubMed ID: 38546551
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma.
    Tannir NM; Signoretti S; Choueiri TK; McDermott DF; Motzer RJ; Flaifel A; Pignon JC; Ficial M; Frontera OA; George S; Powles T; Donskov F; Harrison MR; Barthélémy P; Tykodi SS; Kocsis J; Ravaud A; Rodriguez-Cid JR; Pal SK; Murad AM; Ishii Y; Saggi SS; McHenry MB; Rini BI
    Clin Cancer Res; 2021 Jan; 27(1):78-86. PubMed ID: 32873572
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab - study protocol.
    Janssen JC; van Dijk B; de Joode K; Aarts MJB; van den Berkmortel FWPJ; Blank CU; Boers-Sonderen MJ; van den Eertwegh AJM; de Groot JWB; Jalving M; de Jonge MJA; Joosse A; Kapiteijn E; Kamphuis-Huismans AM; Naipal KAT; Piersma D; Rikhof B; Westgeest HM; Vreugdenhil G; Oomen-de Hoop E; Mulder EEAP; van der Veldt AAM
    BMC Cancer; 2024 May; 24(1):632. PubMed ID: 38783238
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prospective Single-Arm Phase 1 and 2 Study: Ipilimumab and Nivolumab With Thoracic Radiation Therapy After Platinum Chemotherapy in Extensive-Stage Small Cell Lung Cancer.
    Perez BA; Kim S; Wang M; Karimi AM; Powell C; Li J; Dilling TJ; Chiappori A; Latifi K; Rose T; Lannon A; MacMillan G; Saller J; Grass GD; Rosenberg S; Gray J; Haura E; Creelan B; Tanvetyanon T; Saltos A; Shafique M; Boyle TA; Schell MJ; Conejo-Garcia JR; Antonia SJ
    Int J Radiat Oncol Biol Phys; 2021 Feb; 109(2):425-435. PubMed ID: 33002543
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma.
    Potluri R; Ranjan S; Bhandari H; Johnson H; Moshyk A; Kotapati S
    Exp Hematol Oncol; 2019; 8():14. PubMed ID: 31312536
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and Safety of Nivolumab and Ipilimumab for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Cohort Study.
    Iinuma K; Kameyama K; Kawada K; Fujimoto S; Takagi K; Nagai S; Ito H; Ishida T; Kawase M; Kawase K; Nakai C; Kato D; Takai M; Nakane K; Koie T
    Curr Oncol; 2021 Apr; 28(2):1402-1411. PubMed ID: 33916792
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Economic evaluation of nivolumab combined with ipilimumab in the first-line treatment of advanced melanoma in Japan.
    Paly VF; Hikichi Y; Baker T; Itakura E; Chandran N; Harrison J
    J Med Econ; 2020 Dec; 23(12):1542-1552. PubMed ID: 33000994
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nivolumab with or without ipilimumab in pediatric patients with high-grade CNS malignancies: Safety, efficacy, biomarker, and pharmacokinetics-CheckMate 908.
    Dunkel IJ; Doz F; Foreman NK; Hargrave D; Lassaletta A; André N; Hansford JR; Hassall T; Eyrich M; Gururangan S; Bartels U; Gajjar A; Howell L; Warad D; Pacius M; Tam R; Wang Y; Zhu L; Cohen K
    Neuro Oncol; 2023 Aug; 25(8):1530-1545. PubMed ID: 36808285
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM).
    Vasudev NS; Ainsworth G; Brown S; Pickering L; Waddell T; Fife K; Griffiths R; Sharma A; Katona E; Howard H; Velikova G; Maraveyas A; Brown J; Pezaro C; Tuthill M; Boleti E; Bahl A; Szabados B; Banks RE; Brown J; Venugopal B; Patel P; Jain A; Symeonides SN; Nathan P; Collinson FJ; Powles T
    J Clin Oncol; 2024 Jan; 42(3):312-323. PubMed ID: 37931206
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-Effectiveness of Immune Checkpoint Inhibition in BRAF Wild-Type Advanced Melanoma.
    Kohn CG; Zeichner SB; Chen Q; Montero AJ; Goldstein DA; Flowers CR
    J Clin Oncol; 2017 Apr; 35(11):1194-1202. PubMed ID: 28221865
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nivolumab + Tacrolimus + Prednisone ± Ipilimumab for Kidney Transplant Recipients With Advanced Cutaneous Cancers.
    Schenk KM; Deutsch JS; Chandra S; Davar D; Eroglu Z; Khushalani NI; Luke JJ; Ott PA; Sosman JA; Aggarwal V; Schollenberger MD; Sharfman WH; Bibee KP; Scott JF; Loss MJ; Wang H; Qi H; Sharon E; Streicher H; Chen HX; Woodward RN; Bagnasco SM; Taube JM; Topalian SL; Brennan DC; Lipson EJ
    J Clin Oncol; 2024 Mar; 42(9):1011-1020. PubMed ID: 38252910
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma.
    Khushalani NI; Vassallo M; Goldberg JD; Eroglu Z; Kim Y; Cao B; Ferguson R; Monson KR; Kirchhoff T; Amato CM; Burke P; Strange A; Monk E; Gibney GT; Kudchadkar R; Markowitz J; Brohl AS; Pavlick A; Richards A; Woods DM; Weber J
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36450385
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920.
    Emamekhoo H; Olsen MR; Carthon BC; Drakaki A; Percent IJ; Molina AM; Cho DC; Bendell JC; Gordan LN; Rezazadeh Kalebasty A; George DJ; Hutson TE; Arrowsmith ER; Zhang J; Zoco J; Johansen JL; Leung DK; Tykodi SS
    Cancer; 2022 Mar; 128(5):966-974. PubMed ID: 34784056
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term comparative efficacy and safety of nivolumab plus ipilimumab relative to other first-line therapies for advanced non-small-cell lung cancer: A systematic literature review and network meta-analysis.
    O'Byrne K; Popoff E; Badin F; Lee A; Yuan Y; Lozano-Ortega G; Eccles LJ; Varol N; Waser N; Penrod JR; Goring S
    Lung Cancer; 2023 Mar; 177():11-20. PubMed ID: 36669321
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma.
    Zarrabi KK; Handorf E; Miron B; Zibelman MR; Anari F; Ghatalia P; Plimack ER; Geynisman DM
    Oncologist; 2023 Feb; 28(2):157-164. PubMed ID: 36200791
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of BRAF mutation status on clinical outcomes with anti-PD-1 monotherapy versus combination ipilimumab/nivolumab in treatment-naïve advanced stage melanoma.
    Ma VT; Daignault-Newton S; Waninger JJ; Journey S; Chopra Z; Tezel A; Redman BG; Fecher LA; Green MD; Alva AS; Lao CD
    Pigment Cell Melanoma Res; 2021 May; 34(3):629-640. PubMed ID: 33128316
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-world safety of first-line immuno-oncology combination therapies for advanced non-small-cell lung cancer.
    Betts KA; Gao S; Ray S; Schoenfeld AJ
    Future Oncol; 2024 Apr; 20(13):851-862. PubMed ID: 38240151
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stereotactic radiosurgery and combined immune checkpoint therapy with ipilimumab and nivolumab in patients with melanoma brain metastases: A retrospective monocentric toxicity analysis.
    Bodensohn R; Werner S; Reis J; Pazos Escudero M; Kaempfel AL; Hadi I; Forbrig R; Manapov F; Corradini S; Belka C; Theurich S; Heinzerling L; Schlaak M; Niyazi M
    Clin Transl Radiat Oncol; 2023 Mar; 39():100573. PubMed ID: 36655118
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial.
    Cascone T; Leung CH; Weissferdt A; Pataer A; Carter BW; Godoy MCB; Feldman H; William WN; Xi Y; Basu S; Sun JJ; Yadav SS; Rojas Alvarez FR; Lee Y; Mishra AK; Chen L; Pradhan M; Guo H; Sinjab A; Zhou N; Negrao MV; Le X; Gay CM; Tsao AS; Byers LA; Altan M; Glisson BS; Fossella FV; Elamin YY; Blumenschein G; Zhang J; Skoulidis F; Wu J; Mehran RJ; Rice DC; Walsh GL; Hofstetter WL; Rajaram R; Antonoff MB; Fujimoto J; Solis LM; Parra ER; Haymaker C; Wistuba II; Swisher SG; Vaporciyan AA; Lin HY; Wang J; Gibbons DL; Jack Lee J; Ajami NJ; Wargo JA; Allison JP; Sharma P; Kadara H; Heymach JV; Sepesi B
    Nat Med; 2023 Mar; 29(3):593-604. PubMed ID: 36928818
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0-1 non-small cell lung cancer: the INCREASE trial.
    Dickhoff C; Senan S; Schneiders FL; Veltman J; Hashemi S; Daniels JMA; Fransen M; Heineman DJ; Radonic T; van de Ven PM; Bartelink IH; Meijboom LJ; Garcia-Vallejo JJ; Oprea-Lager DE; de Gruijl TD; Bahce I
    BMC Cancer; 2020 Aug; 20(1):764. PubMed ID: 32795284
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.